Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) Director Richard Alistair Stewart sold 20,626 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director directly owned 208,249 shares of the company’s stock, valued at approximately $1,768,034.01. This represents a 9.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Achieve Life Sciences Stock Down 0.4%
ACHV stock opened at $7.99 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.95 and a quick ratio of 0.95. Achieve Life Sciences, Inc. has a 52-week low of $2.62 and a 52-week high of $8.61. The company has a 50-day moving average of $6.35 and a two-hundred day moving average of $5.05. The stock has a market capitalization of $822.17 million, a price-to-earnings ratio of -5.15 and a beta of 2.24.
Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.64). As a group, equities research analysts anticipate that Achieve Life Sciences, Inc. will post -0.91 EPS for the current year.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on ACHV
Institutional Trading of Achieve Life Sciences
Hedge funds have recently modified their holdings of the company. 683 Capital Management LLC bought a new stake in shares of Achieve Life Sciences during the fourth quarter valued at approximately $1,068,000. BlackRock Inc. bought a new position in Achieve Life Sciences in the second quarter worth $34,426,000. Deutsche Bank AG acquired a new stake in Achieve Life Sciences during the second quarter worth $506,000. Alyeska Investment Group L.P. acquired a new stake in Achieve Life Sciences during the second quarter worth $12,575,000. Finally, Jupiter Topco LLC bought a new stake in Achieve Life Sciences in the 2nd quarter valued at $17,964,000. Institutional investors own 33.52% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.
Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.
Featured Articles
- Five stocks we like better than Achieve Life Sciences
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
